Barclays Raises Hims & Hers Target After Novo Deal Clears
Barclays boosts its target on Hims & Hers Health as Novo Nordisk deal removes a key legal overhang, while Progyny see...
This analysis contrasts zero-based budgeting with traditional budgeting, outlining when each method reduces waste and improves clarity.
22,489 articlesBarclays boosts its target on Hims & Hers Health as Novo Nordisk deal removes a key legal overhang, while Progyny see...
The CFTC has intensified oversight of prediction markets, initiating a 45-day rulemaking and new surveillance measure...
Three global e-commerce leaders are trading at bargain prices as reinvestment cycles press on near‑term earnings, pot...
Over the last decade, the iShares S&P 100 ETF led large-cap funds with outsized gains, but 2026’s early volatility hi...
As listings climb in spring 2026, inventory growth making housing is reshaping affordability for buyers, offering mor...
U.S. title insurers posted stronger Q1 2026 results, led by a rebound in commercial activity and gains from automatio...
A transformative bid, a larger regulated footprint, and a path to AI-era resilience. Explore how NextEra Energy's Dom...
May data show rising inflation pressures even as growth slows, with renewed Middle East tensions fanning fears of sta...
A fresh retirement-income blueprint uses a $1 million portfolio anchored by SCHD to target roughly $58,000 per year i...
Tech stocks lead market declines as traders weigh higher-for-longer rates against cooling AI chip enthusiasm and a su...
Broadcom posted a robust Q2 with AI-driven revenue rising sharply, but the stock pulled back. A bold market thesis, h...
SpaceX's potential IPO is being framed by analysts as a possible catalyst for renewed public-market activity after ye...